BusinessAdial Pharmaceuticals Reports $2M Q1 Net Loss, Advances AD04 Program
Adial Pharmaceuticals posted a $2.0 million net loss in Q1 2026, improving from $2.2 million in Q1 2025 due to reduced R&D expenses. The company holds $4.6 million cash, funding operations into late 2026. It is progressing its AD04 program amid favorable FDA policies, collaborating with Molteni Farmaceutici for European commercialization, strengthening intellectual property, and seeking additional funding.
Stockwatch·




